CorMedix (CRMD) Form 4 CorMedix / Steven W Lefkowitz ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Lefkowitz Steven W

(Last) (First) (Middle)

C/O CORMEDIX INC.

1430 US HIGHWAY 206, SUITE 200

(Street)

BEDMINSTER NJ 07921

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2016

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.001 par value per share	06/01/2016		M		100,000	A	$0.68	217,399	D
Common Stock, $0.001 par value per share								174,741	I(1)	Wade Capital Corporation Money Purchase Plan
Common Stock, $0.001 par value per share								10,000	I(1)	Reporting Person's Wife

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.02							(2)	01/09/2024	Common Stock, $0.001 par value per share	200,000		200,000	D
Stock Option (right to buy)	$2.02							(3)	01/09/2024	Common Stock, $0.001 par value per share	30,000		30,000	D
Swries C-3 Non-Voting Convertible Preferred Stock	$1							(4)	(4)	Common Stock, $0.001 par value per share	45,000		4,500	D
Warrant (right to purchase Common Stock)	$0.9(5)							01/08/2015	01/08/2020	Common Stock, $0.001 par value per share	22,500		22,500	D
Series C-3 Non-Voting Convertible Preferred Stock	$1							(5)	(5)	Common Stock, $0.001 par value per share	30,000		3,000	I(1)	Wade Capital Corporation Money Purchase Plan
Warrant (right to purchase Common Stock)	$0.9(5)							01/08/2015	01/08/2020	Common Stock, $0.001 par value per share	15,000		15,000	I(1)	Wade Capital Corporation Money Purchase Plan
Stock Option (right to buy)	$0.9							(6)	03/20/2023	Common Stock, $0.001 par value per share	120,000		120,000	D
Stock Option (right to buy)	$0.68	06/01/2016		M			100,000	(7)	12/05/2022	Common Stock, $0.001 par value per share	100,000	$0.00	0	D
Stock Option (right to buy)	$1.1							(8)	08/11/2021	Common Stock, $0.001 par value per share	30,000		30,000	D
Stock Option (right to buy)	$5.62							(3)	03/01/2025	Common Stock, $0.001 par value per share	50,000		50,000	D
Stock Option (right to buy)	$1.91							(3)	09/20/2017	Common Stock, $0.001 par value per share	75,000		75,000	D

Explanation of Responses:

1. The reporting person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control).

2. The options vested 100% on January 10, 2014.

3. The options vest in full on the first anniversary of the date of grant.

4. On January 8, 2014, the reporting person acquired in a private placement (i) 4,500 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.

5. On January 8, 2014, the reporting person, through his ownership in Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control), acquired in a private placement (i) 3,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.

6. These options vest quarterly over two years beginning June 13, 2013.

7. These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occuured on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.

8. The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.

Remarks:

	Alexander M. Donalson by Power of Attorney	06/03/2016
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.